Why the study?
Emerging data suggested an association between COVID-19 and myocarditis, prompting an evaluation of this association using hospital-based administrative data.
Does COVID-19 infection increase the risk of myocarditis in patients presenting to US hospitals?
Does COVID-19 infection increase the risk of myocarditis in patients presenting to US hospitals?
COVID-19 is significantly associated with a 15.7-fold increased risk for myocarditis, with the highest relative risks observed in patients aged <16 years and ≥75 years.
Answers are grounded in this paper and cite their sources.
Supports myocarditis vigilance in COVID-19 care; extends prior observational associations while leaving causality and interventions open.
Viral infections are a common cause of myocarditis, an inflammation of the heart muscle (myocardium) that can result in hospitalization, heart failure, and sudden death (1). Emerging data suggest an association between COVID-19 and myocarditis (2-5). CDC assessed this association using a large, U.S. hospital-based administrative database of health care encounters from >900 hospitals. Myocarditis inpatient encounters were 42.3% higher in 2020 than in 2019. During March 2020-January 2021, the period that coincided with the COVID-19 pandemic, the risk for myocarditis was 0.146% among patients diagnosed with COVID-19 during an inpatient or hospital-based outpatient encounter and 0.009% among patients who were not diagnosed with COVID-19. After adjusting for patient and hospital characteristics, patients with COVID-19 during March 2020-January 2021 had, on average, 15.7 times the risk for myocarditis compared with those without COVID-19 (95% confidence interval [CI] = 14.1-17.2); by age, risk ratios ranged from approximately 7.0 for patients aged 16-39 years to >30.0 for patients aged <16 years or ≥75 years. Overall, myocarditis was uncommon among persons with and without COVID-19; however, COVID-19 was significantly associated with an increased risk for myocarditis, with risk varying by age group. These findings underscore the importance of implementing evidence-based COVID-19 prevention strategies, including vaccination, to reduce the public health impact of COVID-19 and its associated complications.
No takes yet. Share an insight, caveat, or question.
Boehmer et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: